+357 96 030922
info@marketpublishers.com

Global Viral Vectors and Plasmid DNA Manufacturing Supply, Demand and Key Producers, 2026-2032

https://marketpublishers.com/r/GDA12150DBBBEN.html
Date: January 2026
Pages: 127
Price: US$ 4,480.00 (Single User License)
ID: GDA12150DBBBEN

Abstracts

The global Viral Vectors and Plasmid DNA Manufacturing market size is expected to reach $ 5771 million by 2032, rising at a market growth of 31.1% CAGR during the forecast period (2026-2032).

Viral vectors and plasmid DNA manufacturing represent essential infrastructure in the gene and cell therapy value chain, enabling the delivery and expression of therapeutic genes. Viral vectors—including AAV, adenovirus, and lentivirus—are foundational to CAR-T therapies, gene editing platforms, and vaccine development due to their efficient gene transfer capabilities. Plasmid DNA, as a crucial upstream component, supports viral vector production, mRNA synthesis, and DNA vaccine development. As gene and cell therapies move toward large-scale commercialization, GMP-grade manufacturing capacity of viral vectors and plasmid DNA has become a strategic focal point for biopharma companies, CDMO platforms, and global investors.

As gene and cell therapies gain global regulatory approvals, demand for industrial-scale manufacturing of viral vectors and plasmid DNA is rapidly expanding. Blockbuster CAR-T products, AAV gene therapies, and mRNA vaccines continue to scale up, fueling the need for GMP-compliant platforms, robust quality systems, and high-purity raw materials. CDMO players are becoming the core force in industrial upgrading under the “asset-light” strategies of pharmaceutical companies. Governments worldwide are also promoting bio-manufacturing capacity through strategic funding, infrastructure support, and policy initiatives aimed at localization, modularity, and automation. The industry faces significant technical and operational barriers, including high production costs, lack of standardized processes, and stringent quality control challenges. Key bottlenecks persist in high-purity plasmid preparation and efficient viral vector production, particularly in impurity removal and yield optimization. Regulatory frameworks are

+357 96 030922
info@marketpublishers.com

evolving rapidly across different regions, requiring manufacturers to navigate diverse GMP compliance requirements and stricter approval thresholds. Additionally, the high concentration of capacity among top-tier CDMOs intensifies competition and pricing pressure, raising the market entry threshold for emerging players. The downstream market is transitioning from academic labs and early-stage biotech firms to commercial-stage biopharmaceutical companies, with order volumes scaling from grams to kilograms. AAV, LNP-mRNA, and CAR-T pipelines heavily rely on customized viral vectors and high-quality plasmids. In rare diseases, oncology, and vaccine development, demand is rising for delivery tools with enhanced expression, reduced immunogenicity, and controlled safety. This is driving the construction of scalable, modular GMP manufacturing systems that can meet precise, application-specific requirements.

This report studies the global Viral Vectors and Plasmid DNA Manufacturing demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Viral Vectors and Plasmid DNA Manufacturing, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Viral Vectors and Plasmid DNA Manufacturing that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global Viral Vectors and Plasmid DNA Manufacturing total market, 2021-2032, (USD Million)
Global Viral Vectors and Plasmid DNA Manufacturing total market by region & country, CAGR, 2021-2032, (USD Million)
U.S. VS China: Viral Vectors and Plasmid DNA Manufacturing total market, key domestic companies, and share, (USD Million)
Global Viral Vectors and Plasmid DNA Manufacturing revenue by player, revenue and market share 2021-2026, (USD Million)
Global Viral Vectors and Plasmid DNA Manufacturing total market by Type, CAGR, 2021-2032, (USD Million)
Global Viral Vectors and Plasmid DNA Manufacturing total market by Application, CAGR, 2021-2032, (USD Million)
This report profiles major players in the global Viral Vectors and Plasmid DNA Manufacturing market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key

+357 96 030922
info@marketpublishers.com

companies covered as a part of this study include Thermo Fisher Scientific, Lonza, Azenta Life Sciences, Revvity, VectorBuilder, Takara Bio, GenScript Biotech, Gene Chem, Geno Meditech, PackGene Biotech, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Viral Vectors and Plasmid DNA Manufacturing market

Detailed Segmentation:

Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.

Global Viral Vectors and Plasmid DNA Manufacturing Market, By Region:

United States

China

Europe

Japan

South Korea

ASEAN

India

Rest of World

Global Viral Vectors and Plasmid DNA Manufacturing Market, Segmentation by Type:

AAV

+357 96 030922
info@marketpublishers.com

Lentiviruses

Retroviruses

Adenoviruses

DNA Plasmids

Other

Global Viral Vectors and Plasmid DNA Manufacturing Market, Segmentation by Application:

Pharmaceutical and Biopharmaceutical Companies

Academics and Research Institutes

Companies Profiled:

Thermo Fisher Scientific

Lonza

Azenta Life Sciences

Revvity

VectorBuilder

Takara Bio

GenScript Biotech

Gene Chem

Geno Meditech

+357 96 030922
info@marketpublishers.com

PackGene Biotech

VIROVEK

OriGen

Vector BioLabs

Key Questions Answered

1. How big is the global Viral Vectors and Plasmid DNA Manufacturing market?
2. What is the demand of the global Viral Vectors and Plasmid DNA Manufacturing market?
3. What is the year over year growth of the global Viral Vectors and Plasmid DNA Manufacturing market?
4. What is the total value of the global Viral Vectors and Plasmid DNA Manufacturing market?
5. Who are the Major Players in the global Viral Vectors and Plasmid DNA Manufacturing market?
6. What are the growth factors driving the market demand?

+357 96 030922
info@marketpublishers.com

Contents

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

List Of Tables

LIST OF TABLES

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

List Of Figures

LIST OF FIGURES

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

I would like to order

Product name: Global Viral Vectors and Plasmid DNA Manufacturing Supply, Demand and Key Producers, 2026-2032

Product link: https://marketpublishers.com/r/GDA12150DBBBEN.html

Price: US$ 4,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/GDA12150DBBBEN.html